The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01532934|
Recruitment Status : Completed
First Posted : February 15, 2012
Results First Posted : December 12, 2016
Last Update Posted : December 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|Substance Use Psychopathy||Behavioral: motivational enhancement therapy Other: standard care||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||105 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Impact of Psychopathic Traits on the Efficacy of a Brief Intervention for Substance Use|
|Study Start Date :||August 2009|
|Primary Completion Date :||July 2014|
|Study Completion Date :||July 2014|
Experimental: brief therapy
motivational enhancement therapy for substance use
Behavioral: motivational enhancement therapy
Four 45-minute MET sessions
Other Name: SBIRT; brief motivational intervention
Placebo Comparator: Standard Care
|Other: standard care|
- Percent Days Abstinent Per Month From Drug Use [ Time Frame: three to six months post baseline ]Using timeline followback data, frequency of substance use was assessed for months three through six and presented as average percent days abstinent per month.
- Shortened Inventory of Problems With Alcohol and Drugs (SIP-AD) [ Time Frame: six months ]A measure of consequences of drug and alcohol use across several domains (e.g., social, work, health), SIP-AD scores range from 0-45, with higher scores indicating higher levels of substance use consequences.
- New Criminal Charge [ Time Frame: one year ]New criminal charge vs. no new criminal charge at follow-up as indicated by county database.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01532934
|United States, New York|
|Pretrial Services, Inc.|
|Rochester, New York, United States, 14642|
|Principal Investigator:||Marc T. Swogger, Ph.D.||University of Rochester|